From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

SkinBioTherapeutics – interims, CEO Stuart Ashman contradicts himself again but there’s still a key near-term catalyst

By HotStockRockets | Thursday 27 March 2025


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Life science company focused on skin health SkinBioTherapeutics (SBTX) has announced its results for its half-year ended 31st December 2024 with CEO Stuart Ashman arguing the year “represented a drive for growth through the original corporate platform plus the acquisition of value-added businesses (the M&A strategy) to bring scale and synergies”. Has it really worked though?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

URU…Who R U Kidding?

Sunday »

EZJ

BUY Easyjet

 

PDL

Petra Diamonds Remains a Short

 

Boom

Failed fund manager for PM!

Time left: 12:56:11